OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma (OKYO) said Wednesday it has received "positive feedback" from its US Food and Drug Administration Type D meeting concerning its lead drug candidate urcosimod to treat neuropathic corneal pain. The biopharmaceutical company said the FDA supported urcosimod's advancement into a global phase 3 pivotal trial, and that the regulator's feedback provides increased clarity around its regulatory strategy.